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Abstract
Background: Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor, which is approved
for the treatment of moderate-to-severe rheumatoid arthritis. Authors have found that it prevents lung and
subcutaneous nodulosis in patients with rheumatoid arthritis but, to the best of our knowledge, there are no data
concerning the acceleration of subcutaneous nodulosis during tocilizumab therapy.
Case presentation: We report for the first time a small case series of five patients with rheumatoid arthritis: a
46-year-old white woman, a 70-year-old white woman, a 63-year-old white woman, a 69-year-old white man, and a
72-year-old white woman (mean age 64 ± 10.6 years); they experienced worsening subcutaneous nodulosis during
treatment with intravenously administered tocilizumab.
Four of the five patients were positive for rheumatoid factor and five for anti-citrullinated peptide antibodies. All of
the patients had previously been treated with various conventional and biological drugs; at the time of our observation,
three were taking methotrexate, two hydroxychloroquine, and four were taking prednisone. Tocilizumab 8 mg/kg was
administered intravenously every 4 weeks for a mean of 43.4 ± 32.4 months, and led to good disease control in three
cases. All of the patients had a history of subcutaneous nodulosis, which considerably worsened during tocilizumab
treatment, with the development of new nodules on their fingers, elbows, or in the inframammary fold, tending to
ulcerate. The management of this medical event included discontinuation of methotrexate, the administration of
steroids, the addition of hydroxychloroquine or colchicine, the use of antibiotics, and surgery. However, neither
pharmacological nor surgical treatment was completely effective, as the nodules tended to recur and increased in
number and size.
Conclusions: To the best of our knowledge, this is the first report describing accelerated subcutaneous nodulosis in a
small case series of patients with rheumatoid arthritis treated with tocilizumab.
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Background
Subcutaneous nodulosis describes an extra-articular mani-
festation occurring in patients affected by rheumatoid
arthritis (RA). The nodules may develop in the subcutane-
ous layer of the hands and elbows, on Achilles tendons,
and may also involve the lungs and vocal chords. Nodulo-
sis may be accelerated by concomitant treatment with
methotrexate (MTX) and, to some extent, azathioprine,
leflunomide, and anti-tumor necrosis factor (TNF) agents,
whereas the use of colchicine and hydroxychloroquine
(HCQ) may improve the course of the disease.
The development of subcutaneous nodules in patients
with RA has been explained on the basis of a rheumatic
vasculitis, which is characterized by the precipitation of
immune complexes in the small vessels and the
subsequent activation of the complement cascade. Vessel
inflammation is attributed to the infiltration of poly-
morphonuclear and mononuclear leukocytes, and the
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development of granulomas that are finally responsible for
the formation of nodules.
Subtypes of RA characterized by high titers of rheuma-
toid factor (RF), other autoantibodies, or, more generic-
ally, a high degree of systemic inflammation are the
most susceptible to extra-articular complications, in-
cluding subcutaneous nodulosis. The use of biological
drugs that interfere with the cytokines involved in sys-
temic inflammation, such as interleukin (IL)-6, should
be valuable in preventing the extra-articular manifesta-
tions of RA. Tocilizumab (TCZ) is a monoclonal anti-
body (moAb) directed against the IL-6 receptor that is
approved for the treatment of moderate-to-severe RA,
and some authors have found that it prevents lung and
subcutaneous nodulosis in patients with RA [1, 2] but,
to the best of our knowledge, there are no data concern-
ing the acceleration of subcutaneous nodulosis during
TCZ therapy.
Case presentation
We describe a small case series of five white patients with
RA (one man and four women; mean age 64 ± 10.6 years;
mean disease duration 21.8 ± 10.9 years) who experienced
significant worsening of subcutaneous nodulosis during
treatment with intravenously administered TCZ. Pa-
tients were consecutively recruited from October 2016
to January 2017.
Patient 1
The first case was a 46-year-old white woman who was
nullipara, a non-smoker of tobacco, and unemployed.
Since 1998 she had suffered from RF and anti-citrullinated
peptide antibodies (ACPA)-positive and erosive RA associ-
ated with rheumatoid nodules; she had been treated with
several conventional and biological drugs (MTX, sulfasala-
zine, leflunomide, HCQ, infliximab, etanercept, adalimu-
mab, rituximab, certolizumab, abatacept) plus prednisone
(at a stable dose of 7.5 mg/day throughout the years); all
of the drugs were discontinued for inefficacy or adverse
events. In June 2014 she started intravenously adminis-
tered TCZ 8 mg/kg every 4 weeks plus MTX 10 mg/week
(further increase in dose not tolerated) and HCQ 6 mg/kg
a day, with minimal beneficial effects: C-reactive protein
disease activity score on 28 joints (CRP-DAS28) was > 5.1
at the time of enrollment in the study. In 2006 (under
etanercept therapy), anti-nuclear antibodies (ANA) turned
positive to a 1.160 titer with a homogeneous pattern; anti-
double stranded DNA (dsDNA) and anti-cardiolipin were
always negative at follow-up. In 2010, anti-Ro SSA anti-
bodies were detected despite no report of symptoms of an
overlapping connective tissue disease. Rheumatoid
nodules at the fingers of both her hands, which never
showed a beneficial effect from all of the previous therap-
ies, dramatically increased in size and number during
TCZ treatment. Due to persistent high disease activity and
the increase in the number and size of the rheumatoid
nodules she was swapped to golimumab 50 mg every
month in January 2017, without any further progres-
sion of subcutaneous nodulosis despite poor control
of RA symptoms.
Patient 2
The second case was a 70-year-old, white, menopausal,
non-smoker of tobacco, retired woman. Since 1995 she
had suffered from immunoglobulin M (IgM) RF-
negative, ACPA-positive and erosive RA, and rheuma-
toid nodules. Since 1997 she received MTX 15 mg/week
plus HCQ 400 mg/day, and in 2003, due to poor control
of the disease, she underwent a treatment with intraven-
ously administered infliximab 3 mg/kg every 8 weeks,
which was discontinued in 2014 for a progressive lack of
efficacy and the de novo detection of ANA and anti-
dsDNA (appearing at the eighth infusion and undetect-
able at baseline). Subsequent biologic treatments with
golimumab and abatacept showed no clinical effects;
therefore, intravenously administered TCZ 8 mg/kg
every 4 weeks combined with MTX 15 mg/week was
started in June 2016. Since the start of TCZ, she experi-
enced a progressive worsening of subcutaneous nodulo-
sis in her hands, with nodules tending to cluster and
ulcerate. Moreover, new ulcerating nodules appeared in
her inframammary folds. An antibiotic treatment with
amoxicillin/clavulanate acid 1000 mg/day for 6 consecu-
tive days was prescribed in order to avoid infections. In
December 2016 colchicine 1 mg every other day was
added and MTX discontinued. However, subcutaneous
nodulosis did not ameliorate, although no more ulcera-
tions were reported.
At the time of enrollment (November 2016), RA dis-
ease activity was moderate (CRP-DAS28 4.79), and she
was also taking prednisone 5 mg/day.
Patient 3
The third case was a 63-year-old white woman who was
menopausal, a tobacco smoker, and employed. She was
RF and ACPA-positive, had rheumatoid nodules, and
erosive RA was diagnosed in 1979 at another rheumato-
logic center. Since 2006 she attended our Department and
started receiving orally administered MTX 7.5 mg/week
and etanercept 50 mg/week administered by subcutaneous
injection, both discontinued in 2009 for adverse events.
Subsequently, she was treated with intravenously adminis-
tered rituximab (discontinued for inefficacy), intraven-
ously administered abatacept (discontinued for inefficacy),
and, since April 2010, intravenously administered TCZ
8 mg/kg every 4 weeks in monotherapy (no compliance to
conventional anti-rheumatic drugs), achieving and main-
taining a good clinical response (CRP-DAS28 1.40 at the
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enrollment time). Subcutaneous nodules of her right
elbow and fingers were pre-existent to the introduction of
TCZ. However, 2 months later, she reported a worsening
of subcutaneous nodulosis at the fingers of her left hand
and at her right elbow, which underwent a central ulcer-
ation in February 2013. ANA and other auto-antibodies
were negative at baseline and throughout the follow-up. A
brief course of methylprednisolone 4 mg/day for 4 weeks
and a preventive antibiotic therapy with amoxicillin/clavu-
lanate acid 1000 mg/day for 6 days were prescribed, with
some beneficial effects on ulcer healing.
Patient 4
The fourth case was a 69-year-old white man who was
retired and who smoked tobacco; he had suffered from
RF and ACPA-positive, non-erosive RA since 2009. In
2009 he started a treatment with intravenously adminis-
tered infliximab 3 mg/kg every 8 weeks plus orally ad-
ministered MTX 7.5 mg/week and prednisone 2.5 mg/day
with initial good disease control. In March 2010 his
ANA titer was 1.160, with other autoantibody subsets
negative. In March 2014 he was swapped to intravenously
administered TCZ 8 mg/kg every 4 weeks due to progres-
sive inefficacy and development of rheumatoid nodulosis.
Concomitantly, a subcutaneous nodule of the first finger
of his right hand was removed; the histologic diagnosis
was compatible with a rheumatoid nodule. However, in
April 2014, soon after the introduction of TCZ, he com-
plained from the onset of a new subcutaneous ulcerated
nodule at his left elbow. An antibiotic treatment with
amoxicillin/clavulanate acid 1000 mg/day for 6 consecu-
tive days was started. In July 2014, giving the benefit of
TCZ in clinical disease activity and the risk of precipita-
ting nodulosis, MTX was definitively discontinued. How-
ever, rheumatoid nodules at his fingers increased in
number and, in November 2016, HCQ 200 mg/day was
added. At the enrollment time (November 2016), RA
disease activity was in remission (CRP-DAS28 2.1).
No development of new autoantibody positivity or change
in ANA titration was recorded.
Patient 5
The last case was a 72-year-old white woman who was
menopausal, a non-smoker of tobacco, and a housewife.
In 1990 she was diagnosed as having erosive RF and
ACPA-positive RA and rheumatoid nodules. Since then
she received MTX 7.5 mg/week (further increase in dose
not tolerated) plus prednisone 5 mg/day, with few
improvements in symptoms, and subsequently several bio-
logic drugs (infliximab, etanercept, rituximab, and adali-
mumab), which were all discontinued for adverse events
or inefficacy. During follow-up, her ANA titers fluctuated
from negative to positive values and vice versa (maximum
titer recorded 1.160), whereas anti-dsDNA and other
autoantibodies were persistently negative. In June 2010
she was considered a candidate for intravenously adminis-
tered TCZ 8 mg/kg every 4 weeks, which resulted in good
control of RA (CRP-DAS28 1.74 at the enrollment time,
in November 2016), despite a mild leukopenia (absolute
neutrophil count > 1000/mm3). From 2014 she also
received HCQ 400 mg/day which was permanently
discontinued in 2016 due to visual disturbances. She was
affected by subcutaneous nodules at her elbows and
fingers prior to the start of TCZ; she experienced a
progressive increase in the size and number of the
nodules during the treatment, and these manifestations
partially worsened following the discontinuation of HCQ
(not assumed at the enrollment time).
Table 1 shows the patients’ demographic characteristics.
Discussion
We report five cases of accelerated subcutaneous nodulo-
sis under intravenously administered TCZ 8 mg/kg every
4 weeks for a mean 43.4 ± 32.4 months of treatment.
All the patients had a history of subcutaneous nodulo-
sis, which considerably worsened during treatment with
TCZ. They developed new subcutaneous nodules mainly
on the fingers (Fig. 1a-f ), but also on the elbow or in
the inframammary fold. The nodules had a tendency to
Table 1 Demographic characteristics of the five patients with
rheumatoid arthritis
Patients n = 5
Gender (F/M), n 4/1
Age (years), mean ± SD 64.0 ± 10.6
Disease duration (years), mean ± SD 21.8 ± 10.9
Patients RF-positive, n (%) 4 (80%)
Patients ACPA-positive, n (%) 5 (100%)
Patients ANA-positive, n (%) 4 (80%)
Patients anti-dsDNA-positive, n (%) 1 (20%)
TCZ treatment duration (months),
mean ± SD
43.4 ± 32.4
Patients treated with prednisone
(2.5–7.5 mg/day), n (%)
4 (80%)
Patients treated with methotrexate
(7.5–15 mg/week), n (%)
3 (60%)
Patients treated with hydroxychloroquine
(200–400 mg/day), n (%)
2 (40%)
Demographic characteristics of the five patients included in the study. Four of the
patients were positive for rheumatoid factor and five for anti-citrullinated peptide
antibodies; four patients had anti-nuclear antibodies and one had anti-double-
stranded DNA antibodies. All of the patients had previously been treated with
various conventional and biological drugs; at the time of observation, three were
taking methotrexate at a mean dose ± SD of 11.6 ± 3.8 mg/week with folic acid
supplementation; two were taking hydroxychloroquine at a dose of 300 or
400 mg/day; and four were taking prednisone 2.5–7.5 mg/day. The patients had
also been treated with intravenously administered TCZ 8 mg/kg every 4 weeks
for a mean ± SD of 43.4 ± 32.4 months. ACPA anti-citrullinated peptide antibodies,
ANA anti-nuclear antibodies, dsDNA anti-double stranded DNA, F females, M
males, RF rheumatoid factor, SD standard deviation, TCZ tocilizumab
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ulcerate and released a serous but not purulent fluid,
and perilesional inflammation and local pain greatly af-
fected their quality of life.
As there are still no standardized guidelines, this med-
ical event was managed in various ways, including the
tapering or discontinuation of MTX (two cases), the ad-
ministration of steroids (one case), the addition of HCQ
or colchicine (one case), the use of antibiotics to prevent
infective complications (three cases), and surgery with a
histological examination that revealed a granulomatous
pattern compatible with rheumatoid nodules (one case).
However, neither pharmacological nor surgical treatment
was completely effective as the nodules tended to recur
and increased in number and size. In one case, TCZ was
permanently discontinued because of poor clinical effi-
cacy; the patient was switched to an anti-TNF agent
(golimumab) and is still being followed up.
Subcutaneous nodulosis is the most frequently en-
countered extra-articular manifestation of RA, and oc-
curs in up to 35% of patients [3]. The nodules typically
develop on the dorsal surface of the fingers, the elbows
or Achilles tendons, although they may also involve the
lungs or vocal chords, and are often associated with high
RF or ACPA titers, and a more aggressive and erosive
course of RA. A genetic substrate, cigarette smoking,
and male gender have been controversially associated
with the risk of developing nodulosis [4]. The nodules
are usually characterized histologically by a granuloma-
tous process, with a central area of fibrinoid necrosis
and a peripheral layer of epithelioid macrophages, lym-
phocytes, and histiocytes. There is some evidence that
the nodules may arise as a T helper (Th)1-mediated re-
sponse, and highly express cytokines such TNF-α, IL-10,
IL-15, IL-18, and IL-12 [5, 6] but, interestingly, IL-17
does not seem to be involved in their pathogenesis.
Granulomatous responses are related to the activation of
Th1 lymphocytes and macrophages favoured by the local
production of cytokines such as IL-2 and TNF-α,
whereas IL-17 seems to be mainly involved in lymph
node organization and in the formation of germinal cen-
ters [7]; IL-17 is therefore associated with Th2 and B
lymphocyte activation and antibody production that de-
pend on a distinct immune pathway. By preventing the
maturation of Th-17 lymphocytes and the subsequent
release of IL-17, TCZ may shift the immunological
balance toward a more pronounced Th1 response that
indirectly promotes rheumatic nodulosis, although cur-
rently available data are contrasting [8–10].
The use of MTX (and sometimes azathioprine, leflu-
nomide, and anti-TNF agents) may accelerate the growth
of pre-existing nodules [11–14]. Drug-induced subcuta-
neous nodules have the same clinical and histological
characteristics as RA-related nodules, but the mechan-
ism by means of which the drugs favor subcutaneous
nodulosis while controlling articular symptoms is still
unclear. Genetic susceptibility has been described in
patients carrying the polymorphic variants of methionine
synthase reductase (MTR) or haplotype HLA-DRB1*0401
a b c
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Fig. 1 Subcutaneous nodules on the dorsal surface of the hands of five patients with rheumatoid arthritis treated with tocilizumab. The nodules
tended to cluster and ulcerate (c–e), and were surrounded by an erythematous halo (f) that was associated with local pain and disability
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[15, 16], and some authors have demonstrated that treat-
ment with MTX is associated with the reactivation of Ep-
stein–Barr virus, which may be responsible for the
development of lymphoproliferative disorders or subcuta-
neous nodules [17]. The concomitant use of colchicine,
sulfasalazine, or HCQ seems to improve the course of the
complication, and is therefore recommended in cases in
which the discontinuation of MTX is contraindicated [11].
Anti-TNF-α biologic therapy (for example, infliximab and
etanercept) is commonly used in the management of RA,
especially in patients who are MTX-resistant. There have
been reports of accelerated subcutaneous and lung nodu-
losis in patients with RA, developing early after starting
infliximab or etanercept, perhaps as a result of new auto-
immune phenomena triggered by the neutralization of
TNF-α [12, 18].
To the best of our knowledge, there are no data con-
cerning accelerated subcutaneous nodulosis during treat-
ment with TCZ. Some reports have even highlighted the
usefulness of TCZ in treating lung nodulosis induced by
previous treatment with anti-TNF agents [1], and there
is one case report indicating its beneficial effect on olec-
ranon subcutaneous nodules in a patient with RA [2].
Given its biological properties, TCZ reduces the burden
of systemic inflammation and prevents extra-articular
manifestations, endothelial dysfunction, and vasculitis,
but there are some published reports describing the oc-
currence of dermatological complications such as leuko-
cytoclastic vasculitis and toxidermia [19, 20].
We have observed a visible worsening of subcutaneous
nodulosis in 8.3% of the 60 patients receiving TCZ treat-
ment at our center, which may be related to a change in
the immune response toward more pronounced Th1 acti-
vation. In addition, in our cohort of patients treated with
TCZ, there have also been three cases (5%) with subcuta-
neous nodulosis which, however, remained stable during
the treatment. Further studies are required to clarify the
mechanisms of pathogenesis underlying this association,
and the real incidence of this little known event.
Conclusions
In conclusion, we report for the first time five cases of
accelerating subcutaneous nodulosis in patients with RA
intravenously treated with TCZ. All five patients suffering
from pre-existing rheumatic nodulosis experienced its
severe progression with local inflammation and ulceration.
Our data suggest that a clearer understanding of RA may
allow the identification of subtypes not previously appreci-
ated, finally leading to personalized therapies. However,
given the apparently protective effect of TCZ on the
extra-articular manifestations of RA, the association be-
tween its use and the development/worsening of subcuta-
neous nodulosis deserves further investigations.
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